Global Migraine Market (By Nations - The US, the UK, Germany, France, Italy, Spain and Japan; Drugs - Triptan, CGRP, Others) - Outlook 2024

  • ID: 4586233
  • Report
  • Region: Global, France, Germany, Italy, Japan, Spain, United Kingdom, United States, Great Britain
  • 85 Pages
  • Rockville Research
1 of 4

FEATURED COMPANIES

  • Alder Biopharmaceuticals
  • Amgen Inc
  • Eli Lilly & Company
  • MORE

Migraine is a complex debilitating disorder. It is a form of recurrent headaches often characterized by intense pulsating pain in one side of the head. It is one of the most common disorders of the nervous system. There are various migraine treatment options available in the market depending on the frequency and severity of headaches, the degree of disability caused, and other medical conditions. These treatment options range from conventional medicines to supplements, herbs and various others. Conventional medicine for migraine treatment can be broadly divided into three categories – Abortive, Preventive and Complementary. Some of the common migraine drug classes include Triptan, Calcitonin Gene Related Peptide (CGRP), Tezampanel and Ergots Alkaloids. Triptan dominates acute migraine treatment market.

Global migraine drugs market has been relatively stagnant over past several years. Growth of the industry is attributed to increasing incidences of migraine cases and patent expirations. Rising female population also positively impacts the market as migraine is said to be one of the most common disorders affecting women. However, some of the factors restraining growth of the industry are poor efficacy of drugs, regulatory hurdles and low diagnosis rate of migraine.

The report “Global Migraine Market (By Nations-The US, the UK, Germany, France, Italy, Spain and Japan; Drugs- Triptan, CGRP, Others) - Outlook 2024” provides information on the current scenario, detailed market outlook of the global migraine treatment market with detailed analysis of major drug classes such as Triptan, CGRP and other drug classes. The market is further analysed with detailed market outlook for global as well as regional markets such as North America, Europe and Asia Pacific. The analysis is provided for all the major market across the world such as The US, Germany, France, The UK, Spain, Italy and Japan. Future forecasts of Migraine treatment market overall and across various sub-segments has been provided till 2024, for all the geographies and all the drug classes. Furthermore, major industry players have been prudently analysed in the competitive landscape section of the report in order to provide key comparative insights.

Major industry players operating in the market includes Eli Lilly & Company, Teva Pharmaceutical Industries, Alder Biopharmaceuticals and Amgen Inc. These players are profiled herein based on attributes such as business overview, product segments and financial analysis. It also compiles performance comparison of aforementioned companies and other leading companies in the segment based on various parameters in the competitive landscape section. In totality, the report provides detailed market analysis, with relevant forecasted data supported by key market dynamics. This information will be helpful in evaluating opportunities in global as well as regional migraine market.

READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Alder Biopharmaceuticals
  • Amgen Inc
  • Eli Lilly & Company
  • MORE

1. Executive Summary

2. Research Methodology

3. Migraine
3.1 Overview
3.1.1 Types of Migraine
3.1.2 Stages of Migraine
3.1.3 Symptoms of Migraine
3.1.4 Diagnosis
3.2 Treatment
3.2.1 Abortive Medications
3.2.2 Preventive Medications
3.2.3 Alternative Medicine

4. Market Analysis
4.1 Market Sizing (Actual & Forecasted)
4.2 Market Share Analysis
4.2.1 Market Share by Treatment Drugs
4.2.2 Market Share by Nations

5. Market Segmentation by Drug Class
5.1 Triptan
5.1.1 Overview
5.1.2 Market Sizing (Actual & Forecasted)
5.2 CGRP
5.2.1 Overview
5.2.2 Market Sizing (Actual & Forecasted)
5.3 Others
5.3.1 Overview
5.3.2 Market Sizing (Actual & Forecasted)

6. Migraine Market Regional Analysis
6.1 North America
6.1.1 The US
6.2 Europe
6.2.1 France
6.2.2 Germany
6.2.3 Italy
6.2.4 Spain
6.2.5 The UK
6.3 Asia Pacific
6.3.1 Japan

7. Market Dynamics
7.1 Industry Trends & Development
7.1.1 Anti-CGRP Drugs Pipeline
7.1.2 Neuromodulation Devices for Migraine Treatment
7.1.3 Advent of Migraine Preventive Drug
7.1.5 Availability of Less Expensive Drugs
7.2 Growth Drivers
7.2.1 Increasing Incidence of Migraine Cases
7.2.2 Rising Female Population
7.2.3 Patent Expirations
7.3 Challenges
7.3.1 Poor Efficacy of Drugs
7.3.2 Regulatory Hurdle
7.3.3 Low Diagnosis Rate

8. Competitive Landscape

9. Company Profile
9.1 Eli Lilly & Company
9.2 Teva Pharmaceutical Industries
9.3 Alder Biopharmaceuticals
9.4 Amgen Inc.

List of Figures & Tables
Figure 1: Research Methodology
Table 1: Types of Migraine
Figure 2: Stages of Migraine
Table 2: Treatment Options for Migraine
Figure 3: Global Migraine Drugs Market Size by Value, 2009-17 (US$ Billions)
Figure 4: Global Migraine Market Share by Treatment Drugs Class (2017)
Figure 5: Global Migraine Treatment Drugs Market Share by Nations (2017 & 2024E)
Table 3: Effectiveness of Oral Triptans
Table 4: Cost of Triptan Drug
Figure 6: Global Triptan Drug Sales, 2016-24E (US$ Millions)
Table 5: Anti-CGRP Cass for Migraine Prevention
Table 6: Anti-CGRP Therapies for Migraine Treatment
Table 7: Comparison of CGRP Monoclonal Antibodies
Figure 7: Global CGRP Drug Sales, 2016-24E (US$ Millions)
Table 8: Analysis of ‘Other’ Migraine Treatment Drugs
Figure 8: Global ‘Other’ Migraine Drugs Market Size by Value, 2016-24E (US$ Millions)
Figure 9: North America Migraine Market Size by Value, 2017-24E (US$ Billions)
Figure 10: The US Migraine Market Size by Value, 2017-24E (US$ Billions)
Figure 11: Europe Migraine Market Size by Value, 2017-24E (US$ Billions)
Figure 12: France Migraine Market Size by Value, 2017-24E (US$ Billions)
Figure 13: Germany Migraine Market Size by Value, 2017-24E (US$ Billions)
Figure 14: Italy Migraine Market Size by Value, 2017-24E (US$ Billions)
Figure 15: Spain Migraine Market Size by Value, 2017-24E (US$ Billions)
Figure 16: The UK Migraine Market Size by Value, 2017-24E (US$ Billions)
Figure 17: Asia Pacific Migraine Market Size by Value, 2017-24E (US$ Billions)
Figure 18: Japan Migraine Market Size by Value, 2017-24E (US$ Billions)
Table 9: Migraine Drugs Expected Upcoming FDA Decisions in 2018
Figure 19: Number of Trials of Anti-CGRP Migraine Prophylaxis Drugs by Phase
Table 10: Leading Anti-CGRP Migraine Prophylaxis Drugs Completed Trials by Phase
Figure 20: Leading Anti-CGRP Migraine Prophylaxis Drugs Ongoing and Planned Trial Status
Figure 21: Number of Patients Diagnosed with Migraine Worldwide, 2012-18 (Millions)
Figure 22: Global Female Population, 2009-17 (Billions)
Figure 23: Percentage of Adults in the US with Migraine by Gender, 2008-16
Table 11: Patent Expirations of Migraine Drugs
Table 12: Migraine Drugs Manufacturers Financial Analysis
Table 13: Revenue Comparison of Migraine Market Players
Table 14: Eli Lilly & Company – Migraine Drugs Approved for Marketing
Table 15: Eli Lilly & Company – Migraine Drugs in Pipeline
Figure 24: Eli Lilly & Company Revenue by Business Segment (FY2017)
Figure 25: Eli Lilly & Company Net Sales, FY2013-FY2017 (US$ Billion)
Table 16: Teva - Drugs Approved for Marketing
Table 17: Teva – Migraine Drugs in Pipeline
Figure 26: Teva Pharmaceutical Industries Revenue by Business Segment (FY2017)
Figure 27: Teva Pharmaceutical Industries Net Sales, FY2013-FY2017 (US$ Billion)
Table 18: Alder - Drugs Approved for Marketing
Table 19: Alder– Migraine Drugs in Pipeline
Figure 28: Alder Biopharmaceuticals Revenue by Business Segment (FY2017)
Figure 29: Alder Biopharmaceuticals Net Sales, FY2013-FY2017 (US$ Billion)
Table 20: Amgen Inc. – Migraine Drugs Approved for Marketing
Table 21: Amgen Inc. – Migraine Drugs in Pipeline
Figure 30: Amgen Inc. Revenue by Business Segment (FY2017)
Figure 31: Amgen Inc. Net Sales, FY2013-FY2017 (US$ Billion)

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Eli Lilly & Company
  • Teva Pharmaceutical Industries
  • Alder Biopharmaceuticals
  • Amgen Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll